Dimensional Fund Advisors LP Has $12.35 Million Holdings in RxSight, Inc. (NASDAQ:RXST)

Dimensional Fund Advisors LP raised its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 196.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 359,144 shares of the company's stock after purchasing an additional 237,877 shares during the period. Dimensional Fund Advisors LP owned 0.89% of RxSight worth $12,346,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. Mountain Capital Investment Advisors Inc. boosted its stake in shares of RxSight by 3.8% during the fourth quarter. Mountain Capital Investment Advisors Inc. now owns 8,779 shares of the company's stock valued at $302,000 after purchasing an additional 320 shares in the last quarter. Wells Fargo & Company MN lifted its position in RxSight by 1.7% in the fourth quarter. Wells Fargo & Company MN now owns 26,574 shares of the company's stock valued at $914,000 after purchasing an additional 445 shares during the period. Legal & General Group Plc lifted its position in shares of RxSight by 1.2% during the 4th quarter. Legal & General Group Plc now owns 42,445 shares of the company's stock valued at $1,459,000 after acquiring an additional 512 shares during the period. F M Investments LLC increased its position in RxSight by 12.6% during the 4th quarter. F M Investments LLC now owns 5,901 shares of the company's stock worth $203,000 after purchasing an additional 659 shares in the last quarter. Finally, LPL Financial LLC increased its holdings in shares of RxSight by 3.6% during the 4th quarter. LPL Financial LLC now owns 25,007 shares of the company's stock worth $860,000 after buying an additional 861 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors.

RxSight Trading Down 4.0%

RXST traded down $0.55 during midday trading on Tuesday, hitting $13.20. 953,513 shares of the company traded hands, compared to its average volume of 664,499. RxSight, Inc. has a 52-week low of $13.03 and a 52-week high of $64.50. The company has a market capitalization of $536.41 million, a price-to-earnings ratio of -15.90 and a beta of 1.32. The business has a 50 day simple moving average of $19.02 and a two-hundred day simple moving average of $31.01.

RxSight (NASDAQ:RXST - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.03) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.03). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The firm had revenue of $37.90 million for the quarter, compared to analysts' expectations of $38.74 million. During the same period in the previous year, the company posted ($0.25) earnings per share. RxSight's revenue was up 28.5% compared to the same quarter last year. Equities research analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Tamara Fountain sold 7,000 shares of RxSight stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the transaction, the director now owns 24,793 shares in the company, valued at $637,428.03. This trade represents a 22.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 9.36% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on RXST shares. Needham & Company LLC restated a "buy" rating and set a $43.00 price objective on shares of RxSight in a report on Thursday, April 3rd. Stifel Nicolaus lowered their target price on shares of RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. UBS Group downgraded shares of RxSight from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $45.00 to $16.00 in a research report on Wednesday, April 9th. Wells Fargo & Company decreased their price objective on RxSight from $35.00 to $22.00 and set an "equal weight" rating for the company in a report on Thursday, April 3rd. Finally, Bank of America reiterated an "underperform" rating and set a $22.00 target price (down from $36.00) on shares of RxSight in a research report on Thursday, April 3rd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $37.60.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.